(Q30840104)

17 October 2017

Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1 (English)

1 reference

17 October 2017

1 reference

Thomas M Polasek

1

1 reference

17 October 2017

Matthew P Doogue

series ordinal

2

1 reference

17 October 2017

John O Miners

series ordinal

3

1 reference

17 October 2017

1 December 2011

1 reference

Therapeutic advances in drug safety

17 October 2017

1 reference

17 October 2017

2

1 reference

17 October 2017

6

1 reference

17 October 2017

253-261

1 reference

In vitro efficacy of paraoxonase 1 from multiple sources against various organophosphates

17 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Structure and stereochemistry of the active metabolite of clopidogrel

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Evolution of drug metabolism: hitchhiking the technology bandwagon

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4110838

Clopidogrel-drug interactions

28 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Catapulting clopidogrel pharmacogenomics forward.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2042098611422559

Paraoxonase-1 is a major determinant of clopidogrel efficacy

21 January 2018

1 reference

12 December 2020

Identification and biological activity of the active metabolite of clopidogrel

1 reference

12 December 2020

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting

1 reference

12 December 2020

Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A)

1 reference

12 December 2020

Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel

1 reference

12 December 2020

Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation

1 reference

12 December 2020

The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A

1 reference

12 December 2020

Identifiers

DOI

10.1177/2042098611422559

1 reference

17 October 2017

1 reference

17 October 2017

PubMed publication ID

25083217

1 reference